Sep 7 2012
Here’s a new outcome from the Dabigatran etexilate RE-LY study that suggests there is a gene variant in 1/3 of Caucasians that converts less of the prodrug, reducing the risk of bleeding without reducing efficacy.
Comments (0)
Anticoagulant Therapy
No comments here.